Chimerix (NASDAQ:CMRX) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.07, Fidelity Earnings reports. Chimerix had a negative net margin of 1,162.96% and a negative return on equity of 35.69%. The business had revenue of $1.96 million for the quarter, compared to analyst estimates of $1.30 million.
Shares of NASDAQ CMRX traded up $0.03 during midday trading on Friday, hitting $1.67. The stock had a trading volume of 9,287 shares, compared to its average volume of 1,218,340. The business’s 50 day moving average is $1.78 and its 200-day moving average is $2.77. The company has a market cap of $96.81 million, a P/E ratio of -1.18 and a beta of 1.31. Chimerix has a 52 week low of $1.25 and a 52 week high of $4.40.
In other news, insider Michael T. Andriole bought 100,000 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were purchased at an average price of $1.56 per share, for a total transaction of $156,000.00. Following the completion of the purchase, the insider now owns 100,000 shares in the company, valued at approximately $156,000. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 9.40% of the company’s stock.
Chimerix Company Profile
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Featured Story: Understanding debt-to-equity ratio in fundamental analysis
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.